



TF4

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Rouleau *et al.*

Appl. No. 10/070,664 (U.S. Natl. Stage of  
PCT Appl. No. PCT/CA00/01052)

I.A. Filing Date: September 8, 2000

For: **Diagnosis, Prognosis and Treatment  
of Trinucleotide Repeat-Associated  
Diseases and Intranuclear  
Inclusions-Associated Diseases**

Confirmation No. 9379

Art Unit: *To Be Assigned*

Examiner: *To Be Assigned*

Atty. Docket: 1619.0110000/SRL/AGU

**Information Disclosure Statement**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. A copy of each document is provided.

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following, in regards to non-English language document AL1 cited on Form PTO 1449:

Document **AL1**, French Patent Publication No. 2 764 611 A1, is in the French language. An English language abstract of document AL1 is attached as document **AR3**.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not

be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Angelique G. Uy  
Agent for Applicants  
Registration No. 48,832

Date: 07/11/2002

1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005-3934  
(202) 371-2600



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.  
1619.0110000/SRL/AGUAPPLICATION NO.  
10/070,664APPLICANT  
Rouleau et al.INT'L FILING DATE  
September 8, 2000GROUP  
To Be Assigned

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL1	FR 2 764 611 A1	12/18/1998	France			Yes X No
	AM1	WO 99/29896 A1	06/17/1999	WIPO			Yes No
	AN1	WO 00/26675 A1	05/11/2000	WIPO			Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>1</u>	Brais, B., et al., "Short GCG expansions in the PABP2 gene cause oculopharyngeal muscular dystrophy," Nat. Genet. 18:164-167, Nature Publishing Co. (February 1998)
	AS	<u>1</u>	Davies, S.W., et al., "Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation," Cell 90:537-548, Cell Press (1997)
	AT	<u>1</u>	Davies, S.W., et al., "Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions?" The Lancet 351:131-133, The Lancet Publishing Group (January 1998)

EXAMINER

DATE CONSIDERED

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.  
1619.0110000/SRL/AGUAPPLICATION NO.  
10/070,664APPLICANT  
Rouleau et al.INT'L FILING DATE  
September 8, 2000GROUP  
To Be Assigned**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

**OTHER (Including Author, Title, Date, Pertinent Pages, etc.)**

	AR	<u>2</u>	Gaspar, C., et al., "CAG tract of MJD-1 may be prone to frameshifts causing polyalanine accumulation," <i>Hum. Mol. Genet.</i> 9:1957-1966, Oxford University Press (August 2000)
	AS	<u>2</u>	Ordway, J.M., et al., "Ectopically Expressed CAG Repeats Cause Intranuclear Inclusions and a Progressive Late Onset Neurological Phenotype in the Mouse," <i>Cell</i> 91:753-763, Cell Press (1997)
	AT	<u>2</u>	Scherzinger, E., et al., "Huntingtin-Encoded Polyglutamine Expansions Form Amyloid-like Protein Aggregates In Vitro and In Vivo," <i>Cell</i> 90:549-558, Cell Press (1997)

EXAMINER

DATE CONSIDERED

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.  
1619.0110000/SRL/AGUAPPLICATION NO.  
10/070,664APPLICANT  
Rouleau et al.INT'L FILING DATE  
September 8, 2000GROUP  
To Be Assigned

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

## OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>3</u>	Dialog File 351, Accession No. 1999-070334/19906, Derwent WPI English language abstract for FR 2 764 611 A1 (Document AL1)
	AS		
	AT		

EXAMINER

DATE CONSIDERED

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.